Observational studyJAMA network open2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma.
Neil J Shah et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it